Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

BACKGROUND: We previously demonstrated that brentuximab vedotin (BV) used as second-line therapy in patients with Hodgkin lymphoma is a tolerable and effective bridge to autologous hematopoietic cell transplantation (AHCT). Here, we report the post-AHCT outcomes of patients treated with second-line...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Oncol
Päätekijät: Herrera, A F, Palmer, J, Martin, P, Armenian, S, Tsai, N -C, Kennedy, N, Sahebi, F, Cao, T, Budde, L E, Mei, M, Siddiqi, T, Popplewell, L, Rosen, S T, Kwak, L W, Nademanee, A, Forman, S J, Chen, R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889038/
https://ncbi.nlm.nih.gov/pubmed/29272364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx791
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia